Novel COVID-19 Immunity Test Predicts Both Infection Risk in Healthy Individuals and Disease Severity in Patients
|
By HospiMedica International staff writers Posted on 20 Oct 2020 |
|
Illustration
A novel immunity test for COVID-19 infection that measures cell-mediated immunity to the SARS-CoV-2 coronavirus can aid immunity assessments in individuals who have never been exposed to the virus, and those who may develop short-lived antibodies after exposure to the virus.
Plexision (Pittsburgh, PA, USA) has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research grant to develop the widely available version of PlexCOVID-19, its novel COVID-19 immunity test. Pre-existing cell-mediated immunity has been detected in over half of healthy individuals who have never been exposed to SARS-CoV-2, and reflects prior exposure to other coronaviruses which cause flu-like illness in the general population. This immunity is greatly compromised in severe COVID-19 infection. Therefore, in addition to assessing infection-risk among vulnerable unexposed individuals, cell-mediated immunity can also identify those patients at risk for severe COVID-19 infection.
PlexCOVID-19 is a lab-developed blood test that measures the level of cellular immunity to SARS-CoV-2. Severe forms of COVID-19 infection may be associated with decreased cell-mediated immunity to SARS-CoV-2. Knowledge about cell-mediated immunity to SARS-CoV-2 and therefore, the risk of COVID-19 infection can be combined with available clinical data to assess disease severity in those with COVID-19 infection and the infection risk in vulnerable populations.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”
“We are delighted that the NSF has supported further development of Plexision’s blood test to measure cell-mediated immunity to the novel coronavirus responsible for the COVID-19 pandemic,” said Rajeev Sindhi, Plexision’s CEO. “Defining COVID-19 infection-risk in healthy individuals, and predicting disease severity in patients with this infection are unmet needs of these challenging times. With its strong background in translating immune cell function into clinical solutions, Plexision’s scientific team is committed to improving patient care with personalized risk assessment.”
Related Links:
Plexision
Plexision (Pittsburgh, PA, USA) has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research grant to develop the widely available version of PlexCOVID-19, its novel COVID-19 immunity test. Pre-existing cell-mediated immunity has been detected in over half of healthy individuals who have never been exposed to SARS-CoV-2, and reflects prior exposure to other coronaviruses which cause flu-like illness in the general population. This immunity is greatly compromised in severe COVID-19 infection. Therefore, in addition to assessing infection-risk among vulnerable unexposed individuals, cell-mediated immunity can also identify those patients at risk for severe COVID-19 infection.
PlexCOVID-19 is a lab-developed blood test that measures the level of cellular immunity to SARS-CoV-2. Severe forms of COVID-19 infection may be associated with decreased cell-mediated immunity to SARS-CoV-2. Knowledge about cell-mediated immunity to SARS-CoV-2 and therefore, the risk of COVID-19 infection can be combined with available clinical data to assess disease severity in those with COVID-19 infection and the infection risk in vulnerable populations.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”
“We are delighted that the NSF has supported further development of Plexision’s blood test to measure cell-mediated immunity to the novel coronavirus responsible for the COVID-19 pandemic,” said Rajeev Sindhi, Plexision’s CEO. “Defining COVID-19 infection-risk in healthy individuals, and predicting disease severity in patients with this infection are unmet needs of these challenging times. With its strong background in translating immune cell function into clinical solutions, Plexision’s scientific team is committed to improving patient care with personalized risk assessment.”
Related Links:
Plexision
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Surgical Dressing
ALLEVYN Ag+ SURGICAL
New
Surgical System
Stealth AXiS
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
Critical Care
view channel
Angiography-Based FFR Approach Matches Gold Standard Results Without Wires
Accurately determining whether a coronary stenosis limits blood flow is essential to guide percutaneous coronary intervention, yet wire-based physiologic testing remains underused due to added procedural... Read more
Eye Imaging AI Identifies Elevated Cardiovascular Risk
Many adults at risk for atherosclerotic cardiovascular disease are not identified until they undergo formal primary care assessment. Delayed risk recognition can postpone initiation of statins and lifestyle... Read more
Surgical Techniques
view channel
Fiber-Form Bone Graft Expands Intraoperative Options for Spinal Fusion
Spinal and orthopedic fusion procedures often require bone graft materials that handle predictably and support bone formation. Surgeons face added complexity in difficult anatomy and challenging fusion environments.... Read more
Ultrasound‑Aided Catheter Treatment Cuts Early Collapse in Pulmonary Embolism
Acute pulmonary embolism can cause rapid hemodynamic deterioration and early death in hospitalized and emergency patients. Systemic thrombolysis can dissolve clots but is limited by a high risk of major... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
Voice-Driven AI System Enables Structured GI Procedure Documentation
Documentation during gastrointestinal (GI) procedures often competes with real-time clinical decision-making and imposes a significant cognitive burden on physicians. Manual data entry and post-procedure... Read more
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
